Literature DB >> 20686376

Selected immunohistochemical prognostic factors in endometrial cancer.

Ivana Markova1, Milada Duskova, Marek Lubusky, Milan Kudela, Jana Zapletalová, Martin Procházka, Radovan Pilka.   

Abstract

OBJECTIVE: The objectives of this study were to assess the immunohistochemical expression of p53, bcl-2, c-erbB-2, Ki-67, estrogen (ER) and progesterone (PR) receptors, matrix metalloproteinase-7 and -26 (MMP-7 and MMP-26) in endometrial cancer patients and to assess the relation between steroid receptor positivity and other markers.
DESIGN: Experimental prospective study.
SETTING: Department of Obstetrics and Gynecology, Department of Genetics, Department of Pathology, Palacký University Medical School and University Hospital Olomouc.
METHODS: We studied 144 cases of primary untreated endometrial carcinoma in which the p53, bcl-2, c-erbB-2, Ki-67, ER, PR, MMP-7, and MMP-26 antigens were investigated with the use of immunohistochemical methods. We evaluated the correlations among immunohistochemical staining and the age, International Federation of Gynecology and Obstetrics stage, grading, depth of invasion, and metastatic spread to lymph nodes.
RESULTS: Mean age was 65.7 years (range, 34-90 years). p53, bcl-2, c-erbB-2, Ki-67, ER, and PR were positive in 35 (24.3%), 100 (69.4%), 41 (28.4%), 65 (45.1%), 115 (79.8%), and 127 (88.1%) cases, respectively. Matrix metalloproteinases were evaluated in a group of 70 patients, wherein MMP-7 was positive in 33 patients (47.1%) and MMP-26 was positive in 40 patients (57.1%). The expression of MMP-7 decreased with higher patient age. p53 and Ki-67 overexpression was found to be related to poor differentiation. Immunostaining for bcl-2 correlated with the positivity of steroid receptors status, whereas immunostaining for c-erbB-2 correlated inversely with ER-positive group of cases.
CONCLUSIONS: The overexpression of p53 and Ki-67 seems to indicate a more malignant phenotype, whereas bcl-2 expression in dependence of steroid receptor positivity could contribute to the identification of high-risk tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686376     DOI: 10.1111/IGC.0b013e3181d80ac4

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

2.  Immunohistochemical characterisation of molecular subtypes in endometrial cancer.

Authors:  Sylwia M Łapińska-Szumczyk; Anna M Supernat; Hanna I Majewska; Jacek Gulczyński; Wojciech Biernat; Dariusz Wydra; Anna J Żaczek
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant.

Authors:  A Brunner; P Riss; G Heinze; H Brustmann
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

Review 4.  The significance of markers in the diagnosis of endometrial cancer.

Authors:  Monika M Żyła; Jacek R Wilczyński; Marta Kostrzewa; Kinga Księżakowska-Łakoma; Marek Nowak; Grzegorz Stachowiak; Krzysztof Szyłło; Tomasz Stetkiewicz
Journal:  Prz Menopauzalny       Date:  2016-11-15

5.  Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?

Authors:  Jorge Luis Ramon-Patino; Ignacio Ruz-Caracuel; Victoria Heredia-Soto; Luis Eduardo Garcia de la Calle; Bulat Zagidullin; Yinyin Wang; Alberto Berjon; Alvaro Lopez-Janeiro; Maria Miguel; Javier Escudero; Alejandro Gallego; Beatriz Castelo; Laura Yebenes; Alicia Hernandez; Jaime Feliu; Alberto Pelaez-García; Jing Tang; David Hardisson; Marta Mendiola; Andres Redondo
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

6.  MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.

Authors:  Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Mohammad H Hussein; Saeed Awad M Al-Qahtani; Aly A M Shaalan
Journal:  Oxid Med Cell Longev       Date:  2017-09-20       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.